Secondary stimulation from Bacillus Calmette-Guérin induced macrophages induce nitric oxide independent cell-death in bladder cancer cells

Cancer Letters

Volumn 348, Issue 1-2, 2014, Pages 119-125

  Thiel, Tomas ^a,b   Ryk, Charlotta ^a,b   Chatzakos, Vicky ^a,b,c   Hallén Grufman, Katarina ^a,b   Bavand Chobot, Nasrin ^a,b   Flygare, Jenny ^a   Wiklund, N Peter ^a,b   De Verdier, Petra J ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Bacillus Calmette Gu rin; Cytokines; Nitric oxide; Nitric oxide synthase; Urinary bladder cancer

Indexed keywords

BCG VACCINE; COMPLEMENTARY DNA; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ARTICLE; BACTERIAL GROWTH; BLADDER CANCER; CANCER CELL; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOBLOTTING; IN VIVO STUDY; MACROPHAGE; MICROARRAY ANALYSIS; MYCOBACTERIUM BOVIS BCG; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT;

BACILLUS CALMETTE-GUÉRIN; CYTOKINES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; URINARY BLADDER CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BCG VACCINE; CELL DEATH; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; HUMANS; MACROPHAGES; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARACRINE COMMUNICATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84900513342     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.014     Document Type: Article

References (38)

1. Babjuk M., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 2008, 54(2):303-314.
2. Gontero P., et al. The role of Bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur. Urol. 2009, 57(3):410-429.
3. Klostergaard J., Leroux M.E., Hung M.C. Cellular models of macrophage tumouricidal effector mechanisms in vitro. Characterization of cytolytic responses to tumour necrosis factor and nitric oxide pathways in vitro. J. Immunol. 1991, 147(8):2802-2808.
4. Ratliff T.L., Gillen D., Catalona W.J. Requirement of a thymus dependent immune response for BCG-mediated antitumour activity. J. Urol. 1987, 137(1):155-158.
5. Yamada H., et al. Enhancing effect of an inhibitor of nitric oxide synthesis on Bacillus Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro. Jpn. J. Cancer Res. 2000, 91(5):534-542.
6. Luo Y., et al. Role of Th1-stimulating cytokines in Bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin. Exp. Immunol. 2006, 146(1):181-188.
7. Bohle A., et al. Elevations of cytokines interleukin-1, interleukin-2 and tumour necrosis factor in the urine of patients after intravesical Bacillus Calmette-Guérin immunotherapy. J. Urol. 1990, 144(1):59-64.
8. Oswald I.P., et al. NO as an effector molecule of parasite killing: modulation of its synthesis by cytokines. Comp. Biochem. Physiol. Pharmacol. Toxicol. Endocrinol. 1994, 108(1):11-18.
9. Prescott S., et al. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J. Urol. 1990, 144(5):1248-1251.
10. Farias-Eisner R., et al. Nitric oxide is an important mediator for tumouricidal activity in vivo. Proc. Natl. Acad. Sci. USA 1994, 91(20):9407-9411.
11. Jenkins D.C., et al. Roles of nitric oxide in tumour growth. Proc. Natl. Acad. Sci. USA 1995, 92(10):4392-4396.
12. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2(10):907-916.
13. Jansson O.T., et al. The role of nitric oxide in Bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer. Br. J. Cancer 1998, 78(5):588-592.
14. Hosseini A., et al. Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG treated bladder cancer. Nitric Oxide 2006, 15(4):337-343.
15. Koskela L.R., et al. Localization and expression of inducible nitric oxide synthase in patients after BCG treatment for bladder cancer. Nitric Oxide 2012, 27(3):185-191.
16. Wolf H., Haeckel C., Roessner A. Inducible nitric oxide synthase expression in human urinary bladder cancer. Virchows Arch. 2000, 437(6):662-666.
17. Swana H.S., et al. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J. Urol. 1999, 161(2):630-634.
18. Sandes E.O., et al. Expression of inducible nitric oxide synthase in tumoural and non-tumoural epithelia from bladder cancer patients. Nitric Oxide 2005, 12(1):39-45.
19. Mitropoulos D., et al. The effect of intravesical Bacillus Calmette-Guérin instillations on the expression of inducible nitric oxide synthase in humans. Nitric Oxide 2005, 13(1):36-41.
20. Pryor K., et al. Bacillus Calmette-Guérin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br. J. Cancer 1995, 71(4):801-807.
21. Rajala P., et al. Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol. Res. 1992, 20(3):215-217.
22. Alvarez V., et al. Inhibition of Bacillus Calmette-Guérin-induced nitric oxide in bladder tumour cells may improve BCG treatment. Int. J. Mol. Med. 2005, 16(4):565-571.
23. Bohle A., et al. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J. Urol. 1993, 150(6):1932-1937.
24. Mizutani Y., et al. Effects of Bacillus Calmette-Guérin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer 1992, 69(2):537-545.
25. Kurisu H., et al. Cytokine-mediated antitumour effect of Bacillus Calmette-Guérin on tumour cells in vitro. Cancer Immunol. Immunother. 1994, 39(4):249-253.
26. Ehren I., et al. Measurement of luminal nitric oxide in bladder inflammation using a silicon balloon catheter: a novel minimally invasive method. Urology 1999, 54(2):264-267.
27. Connelly L., et al. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J. Immunol. 2001, 166(6):3873-3881.
28. Umansky V., et al. Co-stimulatory effect of nitric oxide on endothelial NF-kappaB implies a physiological self-amplifying mechanism. Eur. J. Immunol. 1998, 28(8):2276-2282.
29. Brandau S., Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed. Pharmacother. 2007, 61(6):299-305.
30. Morcos E., et al. Endogenously formed nitric oxide modulates cell growth in bladder cancer cell lines. Urology 1999, 53(6):1252-1257.
31. Gallo O., et al. Role of nitric oxide in angiogenesis and tumour progression in head and neck cancer. J. Natl. Cancer Inst. 1998, 90(8):587-596.
32. Radomski M.W., et al. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res. 1991, 51(22):6073-6078.
33. Thomsen L.L., et al. Nitric oxide synthase activity in fresh cells from ovarian tumour tissue: relationship of enzyme activity with clinical parameters of patients with ovarian cancer. Biochem. Pharmacol. 1998, 56(10):1365-1370.
34. Takeda K., et al. Anti-tumour activity of fucoidan is mediated by nitric oxide released from macrophages. Int. J. Oncol. 2012, 40(1):251-260.
35. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumour progression and metastasis. Cell 2010, 141(1):39-51.
36. Shree T., et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011, 25(23):2465-2479.
37. Brune B., Golkel C., von Knethen A. Cytokine and low-level nitric oxide prestimulation block p53 accumulation and apoptosis of Raw 264.7 macrophages. Biochem. Biophys. Res. Commun. 1996, 229(2):396-401.
38. Belgorosky D., et al. Inhibition of nitric oxide is a good therapeutic target for bladder tumours that express iNOS. Nitric Oxide 2014, 36:11-18.